<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Histidine-based ionizable cationic surfactants: novel biodegradable agents for hydrophilic macromolecular drug delivery</title>
				<funder ref="#_C6EERrT">
					<orgName type="full">EUREGIO</orgName>
				</funder>
				<funder>
					<orgName type="full">University of Innsbruck and Medical University of Innsbruck</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2023-12-26">26 December 2023</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Ilaria</forename><surname>Polidori</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pharmaceutical Technology</orgName>
								<orgName type="department" key="dep2">Institute of Pharmacy</orgName>
								<orgName type="department" key="dep3">Center for Chemistry and Biomedicine</orgName>
								<orgName type="institution">University of Innsbruck</orgName>
								<address>
									<postCode>6020</postCode>
									<settlement>Innsbruck</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dennis</forename><surname>To</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pharmaceutical Technology</orgName>
								<orgName type="department" key="dep2">Institute of Pharmacy</orgName>
								<orgName type="department" key="dep3">Center for Chemistry and Biomedicine</orgName>
								<orgName type="institution">University of Innsbruck</orgName>
								<address>
									<postCode>6020</postCode>
									<settlement>Innsbruck</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gergely</forename><surname>Kali</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pharmaceutical Technology</orgName>
								<orgName type="department" key="dep2">Institute of Pharmacy</orgName>
								<orgName type="department" key="dep3">Center for Chemistry and Biomedicine</orgName>
								<orgName type="institution">University of Innsbruck</orgName>
								<address>
									<postCode>6020</postCode>
									<settlement>Innsbruck</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Bernkop-Schnürch</surname></persName>
							<idno type="ORCID">0000-0003-4187-8277</idno>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pharmaceutical Technology</orgName>
								<orgName type="department" key="dep2">Institute of Pharmacy</orgName>
								<orgName type="department" key="dep3">Center for Chemistry and Biomedicine</orgName>
								<orgName type="institution">University of Innsbruck</orgName>
								<address>
									<postCode>6020</postCode>
									<settlement>Innsbruck</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Andreas Bernkop-Schnürch</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Histidine-based ionizable cationic surfactants: novel biodegradable agents for hydrophilic macromolecular drug delivery</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2023-12-26">26 December 2023</date>
						</imprint>
					</monogr>
					<idno type="MD5">0FBD23510FB711286E1F4380B283D84A</idno>
					<idno type="DOI">10.1007/s13346-023-01511-8</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-05-25T07:17+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Histidine</term>
					<term>Biodegradable surfactants</term>
					<term>Ionizable cationic lipids</term>
					<term>Hydrophobic ion-pairing</term>
					<term>DNA delivery</term>
					<term>Lipid-based formulations</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The aim of this study was to design surfactants based on histidine (His) for hydrophobic ion-pairing and evaluate their safety and efficacy. Lauryl, palmitoyl and oleyl alcohol, as well as 2-hexyl-1-decanol were converted into surfactants with histidine as head-group via esterification. The synthesized His-surfactants were characterized regarding pK a , critical micellar concentration (CMC), biodegradability, toxicity on Caco-2 cells, and ability to provide endosomal escape. Furthermore, the suitability of these agents to be employed as counterions in hydrophobic ion pairing was evaluated. Chemical structures were confirmed by 1 H-NMR, FT-IR, and MS. The synthesized surfactants showed pK a values ranging from 4.9 to 6.0 and CMC values in the range of 0.3 to 7.0 mM. Their biodegradability was proven by enzymatic cleavage within 24 h. Below the CMC, His-surfactants did not show cytotoxic effects on Caco-2 cells (cell viability &gt; 80%). All His-surfactants showed the ability to provide endosomal escape in a pH-dependent manner in the range of 5.2 to 6.8. Complexes formed between Hissurfactants and heparin or plasmid DNA (pDNA) via hydrophobic ion pairing showed at least 100-fold higher lipophilicity than the correspondent model drugs. According to these results, His-surfactants might be a promising safe tool for delivering hydrophilic macromolecular drugs and nucleic acids.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">Introduction</head><p>The term ´biopharmaceuticals´ refers to a heterogeneous class of therapeutical hydrophilic macromolecular drugs such as peptides, proteins, polysaccharides, monoclonal antibodies, and, more recently, nucleic acids <ref type="bibr" target="#b0">[1]</ref>. The majority of these drugs are typically administered via the parenteral route. Despite overcoming stability issues related to the harsh environment in the gastrointestinal tract (GIT), the parenteral route bears disadvantages such as frequent and painful administrations leading to scarce patients' compliance. Therefore, there is a high demand for alternative administration routes. Among all the developed drug delivery systems, lipid-based formulations (LBF) offer a potential non-invasive alternative to parenteral administration.</p><p>Examples of lipid-based formulations are represented by oil-in-water nanoemulsions, self-emulsifying drug delivery systems (SEDDS), solid lipid nanoparticles (SLN), nanostructure lipid carriers (NLC), liposomes, and micelles <ref type="bibr" target="#b1">[2]</ref>. Among those, SEDDS have already proven to provide protection against the acidic pH of the stomach <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref> and enzymatic degradation <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref>, improved mucus permeation properties <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8]</ref>, and cellular uptake, which in turn leads to an improved bioavailability <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b7">8]</ref>. In order to develop a stable and effective delivery system for these hydrophilic therapeutics, it is required to incorporate such macromolecular drugs into lipophilic systems. Hydrophobic ion pairing (HIP) seems to be the most promising strategy to alter the solubility of hydrophilic drugs without chemical modification <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref>. In this approach, hydrophilic drugs bearing one or more charges are co-precipitated thanks to establishing an ionic interaction with a counterion bearing one or more opposite charges and at least one hydrophobic domain <ref type="bibr" target="#b8">[9]</ref>. Among the different types of available counterions, surfactants are the most employed for this purpose <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>. However, the major drawback connected to the use of these agents is that their cationic nature has been proven to be responsible for cellular, nuclear, and mitochondrial membrane destabilization <ref type="bibr" target="#b17">[18]</ref>, generation of reactive oxygen species <ref type="bibr" target="#b18">[19]</ref> and DNA damage <ref type="bibr" target="#b19">[20]</ref>. The negative impact of commonly employed cationic surfactants on soils, aquatic life, and humans led to the increased demand for safer and biodegradable alternatives. Ideally, the next generation of safer cationic agents is in-vivo degraded into non-toxic, preferably endogenous, building blocks. On the one hand, a recent solution to circumvent this problem is represented by spreading the positive charge of the cationic head by delocalizing it into a heterocyclic ring (imidazolium or pyridinium polar head) <ref type="bibr" target="#b20">[21]</ref>. On the other hand, the design of such compounds could be inspired by naturally occurring, non-toxic compounds. Still, these new agents need to be able to form lipophilic complexes via ionic interactions with a variety of therapeutic compounds to increase their lipophilic properties, facilitating their incorporation into LBF. A couple of research groups have already investigated the safety of new cationic surfactants that bear mainly arginine and lysine as cationic head groups <ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref> and are able to be degraded into non-harmful building blocks. Nonetheless, to the best of our knowledge, no investigation has been conducted on the potential use of histidine as polar head group of counterions for hydrophobic ion pairing. The use of histidine can be advantageous due to the pK a of the imidazolium ring of 6.0-6.1, which allows to obtain compounds that can bear a positive charge on the imidazolium ring only at relatively low pH values. This property can be exploited to form electrostatic interactions with a variety of therapeutics and to destabilize the endosomal membrane after cellular uptake. Therefore, this study aims to evaluate the safety of surfactants based on histidine as head group and naturally occurring fatty alcohols connected via ester bond in order to provide biodegradability. The newly produced His-surfactants were characterized regarding their physicochemical properties (CMC, pK a ), their enzymatic biodegradability and toxicity on Caco-2 cell line, as well as their potential to allow endosomal escape. Their suitability and efficiency as hydrophobic ion pairing agents was evaluated by using heparin and plasmid DNA (pDNA) as model drugs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials</head><formula xml:id="formula_0">Tert-butyl-4-[(2 S)-3-(2,5-dioxopyrrolidin-1-yl)oxy-2- [(2-methylpropan-2-yl)oxycarbonylamino]-3-oxopropyl]</formula><p>imidazole-1-carboxylate (Boc-His(Boc)-OSu) was obtained from Bachem (Switzerland). L-histidine, lauryl alcohol, 1-hexadecanol, 2-hexyl-1-decanol, calcium chloride, sodium chloride, sodium hydroxide, sodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, trifluoroacetic acid, Triton-X 100, dichloromethane anhydrous, methanol, 4-dimethylaminopyridine (DMAP), potassium permanganate and trypsin from porcine pancreas (1000-2000 BAEE units/mg) were obtained from Sigma-Aldrich (Vienna, Austria). 2,2-Bis(hydroxymethyl)-2,2′,2′′-nitrotriethanol (BIS-TRIS, ≥ 98%), heparin, and oleyl alcohol (technical grade 85%) were obtained from Fisher Scientific (Austria). The human erythrocyte concentrate was kindly provided by Tirol Kliniken (Innsbruck, Austria). All other chemicals, reagents, and solvents were obtained from commercial sources.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>General procedure for the synthesis of his-surfactants</head><p>His-surfactants were synthesized as represented in Fig. <ref type="figure" target="#fig_2">1</ref>. Briefly, 1 mmol of Boc-His(Boc)-OSu, 1.2 mmol of fatty alcohol, and 0.12 mmol of 4-dimethylaminopyridine (DMAP) were dissolved in 3 mL of dichloromethane (DCM). The mixture was continuously stirred at 35 °C for 14 h. The progress of the reaction was monitored by thin layer chromatography (TLC), using a mobile phase composed of chloroform/ethyl acetate (1:1, V/V) on a 0.5 mm thick precoated silica gel aluminum sheet as stationary phase. The plate was sprayed with an aqueous solution composed of 0.5 M dipotassium carbonate and 1 M NaOH (50:14, V/V) containing 0.06 M potassium permanganate and subsequently heated to obtain visible yellow spots. After the completion of the reaction, the mixture was dried with a rotary evaporator (Heidolph VAP Value G3B, Heidolph Instruments, Germany). Subsequently, the removal of BOC protecting groups to yield the final products was achieved by dissolving the solids in 5 mL of dichloromethane/trifluoroacetic acid (TFA) (9:1, V/V) under continuous stirring. The reaction was kept at room temperature for 30 min and the progress of the reaction was monitored by TLC using precoated silica gel RP-18 W aluminum sheets using a mobile phase composed of demineralized water/acetonitrile (6:4, V/V) and 0.1% TFA. The TLC plate was sprayed with 0.5% (m/V) ninhydrin solution as detection reagent. The mixture was dried under vacuum to remove excess of TFA, and a reversed-phase column chromatography was performed in order to remove residual educts and side products. For this, silica gel C18 (pore size 60 Å, particle size 35-70 μm) was used as stationary phase, while water/acetonitrile (6:4, V/V) and 0.1% TFA was used as mobile phase. Eluted fractions in 2 mL volume were collected and analysed by TLC, as mentioned before. Afterward, the purified product was obtained from selected fractions by freeze-drying. Final products were stored at -20 °C until further use. FT-IR, 1 H-NMR, and MS spectra of all compounds are reported in Supplementary materials (S1-S6). Histidine-palmitoyl ester (HPE) Boc-His(Boc)-OSu (452.46 mg, 1 mmol), palmitoyl alcohol (290.9 mg, 1.2 mmol) and DMAP (14.7 mg, 0.12 mmol) were dissolved in 3 mL of DCM and kept under continuous stirring for 14 h at 35 °C. Subsequently, removal of Boc groups and purification yielded a white solid (336 mg, yield 60.4%). IR ν max 2919, 2851 (sp 3 -CH), 1689 (ester C = O), 1140 cm -1 (ester C-O). 1   <ref type="bibr" target="#b24">(25)</ref>, 407.6 <ref type="bibr" target="#b9">(10)</ref>.</p><p>Histidine-2-hexyl-1-decanol ester (HDE) Boc-His(Boc)-OSu (452.46 mg, 1 mmol), 2-hexyl-1-decanol (290.9 mg, 1.2 mmol) and DMAP (14.7 mg, 0.12 mmol) were dissolved in 3 mL of DCM and kept under continuous stirring for 14 h at 35 °C. Subsequently, removal of Boc groups and purification yielded a white solid (270 mg, yield 45.4%). IR ν max 2928, 2858 (sp 3  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Chemical characterization of his-surfactants</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FT-IR</head><p>FT-IR spectra were recorded on a Bruker ALPHA FT-IR equipped with a Platinum ATR sampling module and analysed with OPUS Spectroscopy Software, version 7. FT-IR spectra were recorded at a resolution of 4 cm -1 in the wavenumber range from 4000 to 400 cm -1 .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">H-NMR</head><p>1 H-NMR measurements were performed on a "Mars" 400 MHz Avance 4 Neo spectrometer from Bruker Corporation (Billerica, MA, USA, 400 MHz) in dimethyl sulfoxided 6 (DMSO-d 6 ) solution. Chemical shifts were reported in parts per million, and deuterated solvent, DMSO-d 6 , served as the internal standard (δ 2.5 ppm).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MS</head><p>The molecular mass of His-surfactants was determined using MS according to a method described <ref type="bibr" target="#b27">[28]</ref> with some modifications. Mass spectrometry detection was carried out using a Chromaster 5610 MS detector (Hitachi) controlled by a computer running the MSD system manager software (version 2.1). Analysis conditions were set as follows: ionization potential (V): 2500; counter gas flow (L/min): 0.6; AIF temperature 120 °C; ion source temperature 70 °C; API temperature 120 °C; AIF introducing energy (eV): 5.0; AIF excreting voltage (V): 5.0; AP1 voltage (V): 80.0 and AP2 voltage (V): 30.0. Sample solutions were prepared by dissolving His-surfactants in methanol at a concentration of 1 mg/mL and 2 µL were injected. Mass spectral studies were performed in positive electrospray ionization (ESI) mode in the mass range of m/z 250-400 for histidine-lauryl ester (HLE), and 300-800 for histidine-palmitoyl ester (HPE), histidine-oleyl ester (HOE) and histidine-(2-hexyl-1-decyl) ester (HDE) to determine molecular weights.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Determination of CMC and pK a</head><p>The critical micellar concentration was determined using a previously described method <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b28">29]</ref>. Briefly, the surface tension of unbuffered aqueous solutions and solutions at pH 2 of HLE, HPE, HOE, and HDE at different concentrations ranging from 0.1 to 10 mM was recorded using the drop shape analysis instrument Kruess DSA25E (Kruess, D-Hamburg, Germany). Using the pendant drop technique at ambient conditions, the surface tension of all aqueous solutions was measured in series of 3 drops each. The drop was suspended from a needle (outside diameter: 1.83 mm), and the drop volume was increased by a dosimeter. The pK a values of HLE, HPE, HOE, and HDE were determined by titration of 10 mL of 1 mM surfactant solution with 0.25 mM NaOH at 25 °C using a pH electrode (WTW SenTix Mic). The inflection point was determined by interpolating the points and smoothing the curve and the corresponding pK a values were calculated as the semi-equivalent point of the neutralization curve <ref type="bibr" target="#b28">[29]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HPLC quantification of his-surfactants</head><p>The system consisted of a Hitachi Chromaster (Tokyo, Japan) equipped with a 5160 pump, 5260 autosampler, 5310 column oven, and 5430 photodiode array UV detector. In brief, the stationary phase was a Primesep 100 column (150 × 4.6 mm, 5 μm), the column oven was set to 30 °C.</p><p>For isocratic elution ACN/H 2 O (90:10, V/V) containing H 2 SO 4 0.2% V/V with a flow rate of 1.5 mL/min was used as mobile phase. The detection wavelength was set to 220 nm.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biodegradation studies</head><p>The biodegradability of the newly synthesized Hissurfactants was evaluated by applying a slightly modified method described by Strader et al. <ref type="bibr" target="#b29">[30]</ref>. Briefly, HLE, HPE, and HOE were dissolved in 100 mM HEPES buffer pH 6.8 at a concentration of 1 mg/ml. In an Eppendorf tube, 400 µL of the surfactant stock solution was mixed with 500 µL of 100 mM HEPES buffer pH 6.8 and 100 µL of a trypsin stock solution at a concentration of 1 mg/ml prepared in 1 mM HCl. Samples were incubated for 24 h and continuously agitated at 300 rpm. At predetermined time points (10 min, 30 min, 1 h, 2 h, 4 h, and 24 h), an aliquot of 50 µL was withdrawn from every tube and 1 µL of TFA was immediately added to stop the enzymatic degradation. The amount of remaining surfactant was evaluated by HPLC quantification as described above.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxicity studies</head><p>Caco-2 cells were seeded at a density of 2.5 × 10 4 cells per well in 24 well plates. During the growth period, cells were stored in minimum essential medium (MEM) at 37 °C, 95% relative humidity, and 5% CO 2 . MEM was supplied with 10% (V/V) heat-inactivated fetal bovine serum (FBS) and penicillin/streptomycin solution (100 units/0.1 mg/L). Cells were cultured until confluency of 80-90% was obtained, and the medium was replaced every two days until the day of the experiment. Test solutions of HLE, HPE, HOE, and HDE were prepared in concentrations of double the CMC, at the CMC and half the CMC, respectively, in sterile 25 mM HEPES buffered saline (HBS) composed of 20 mM HEPES, 1 g/L glucose anhydrous, 136.7 mM NaCl, 5 mM KCl and 1 mM CaCl 2 , pH 7.4. Before applying the samples, cells were washed twice with pre-heated HBS at 37 °C. Test solutions, negative control (HBS), and positive control (0.1% V/V Triton X-100) were added in triplicate to the cell culture plate in the volume of 0.5 mL/well and incubated at 37 °C in a 5% CO 2 environment for 4 h. After incubation, cells were washed again three times. Subsequently, HBS was replaced with a 0.1% (m/V) resazurin solution in HBS and incubated for 3 h. Cell viability was determined photometrically at an excitation wavelength of 540 nm and an emission wavelength of 590 nm. Cell viability was calculated according to the following equation:</p><formula xml:id="formula_1">Cell viability (%) ∶ F(sample) -F(negative control) F(positive control) -F(negative control) × 100</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Endosomal Escape studies</head><p>The capacity of His-surfactants to induce pH-dependent disruption of lipid bilayer membranes was assessed via a red blood cell hemolysis assay following a slightly modified method described in the literature <ref type="bibr" target="#b30">[31]</ref>. Briefly, surfactants were incubated for 1 h at 37 °C in the presence of human erythrocytes at concentrations ranging from 5 to 50 µg/mL in 100 mM sodium phosphate buffer (supplemented with 150 mM NaCl) in the pH range of the endosomal processing pathway (7.4, 7.0, 6.6, 6.2, and 5.8). The extent of cell lysis was determined spectrophotometrically by measuring the amount of hemoglobin released at 415 nm and normalized to a 100% lysis control (0.1% V/V Triton X-100).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Preparation of hydrophobic ion pairs</head><p>Heparin and pDNA were used as model drugs for HIP. The plasmid DNA pcDNA3-EGFP was amplified in Escherichia coli cells and purified using a plasmid-extraction kit from Qiagen. The purified plasmid was dissolved in nuclease-free water and stored at -20 °C until use. The concentration was determined using the NanoQuant Plate (Tecan Spark®, Tecan Trading AG, Zurich, Switzerland), and a gel electrophoresis was performed as control. Surfactant solutions in different concentrations were prepared in aqueous solution of HCl 0.01 M. The individual solution was added dropwise to the same volume of heparin solution (1 mg/mL) at pH 2.0 or pDNA (1 mg/mL) at pH 8.0 resulting in molar ratios ranging from 1:2 to 1:50 (heparin:surfactant) or from 1:6159 to 1:18477 (pDNA:surfactant). Solutions of heparin/pDNA and pure surfactant solutions in the same concentrations served as controls. Afterward, mixtures were incubated at room temperature for 15 min while gently shaking on a thermomixer at 300 rpm. Subsequently, HIPs and supernatants were separated by centrifugation at 12,500 rpm for 15 min at 4 °C. The obtained HIP complexes were washed twice with water, dried under vacuum, and stored at -20 °C until further use. Precipitation efficiency was calculated using the following equation:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Precipitation efficiency of heparin</head><p>The remaining heparin in the supernatants was quantified as described by Liu et al. <ref type="bibr" target="#b31">[32]</ref>. Briefly, 0.001 M TBO solution was prepared in 0.03 M sodium chloride in 0.01 M HCl. Supernatant and TBO solutions were mixed in equal volume ratio and incubated at 37 °C and 300 rpm for 4 h. Heparin and TBO complex precipitated in the mixture and was separated by centrifugation at 6000 rpm for 10 min. The Precipitation efficiency (%) = 100 -drug concentration after HIP drug concentration before HIP × 100</p><p>precipitate was carefully washed three times with 0.03 M sodium chloride in 0.01 M HCl and re-dissolved in the mixture of 80% ehanol and 0.1 M NaOH (4/1, V/V). The absorbance of the solution was measured at 530 nm. Heparin concentration was calculated from the calibration curve constructed using known concentration range of heparin (0.25-0.03 mg/mL) by TBO assay in the same manner.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Precipitation efficiency of pDNA</head><p>The amount of the precipitated pDNA was calculated through the remaining pDNA in the supernatant spectrophotometrically determined using the NanoQuant Plate (Tecan Spark®, Tecan Trading AG, Zurich, Switzerland) at a wavelength of 260 nm.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characterization of hydrophobic ion pairs</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Partition coefficient</head><p>HIPs were further characterized regarding their partition coefficient in water and octanol (logP n-octanol/water ). Hissurfactant solution (200 µL, 1:20 or 1:18477 molar ratio) was slowly added dropwise to heparin or pDNA aqueous solution (200 µL, 1 mg/mL) at room temperature. Demineralized water added to heparin or pDNA aqueous solution served as control. After five minutes, octanol (400 µL) was added to the mixture and samples were placed on a thermomixer at 300 rpm and 25 °C for 24 h. The two phases were separated by centrifugation for 15 min at 12,500 rpm. Aliquots of 100 µL were withdrawn from each octanol phase, diluted with 100 µL of 0.1 M NaOH, and vortexed for 20 min to break the ionic interaction. Heparin was quantified via TBO assay as described above after the addition of 100 µL of 0.1 M HCl to neutralize the excess of NaOH. The amount of pDNA in water and octanol phase was determined as described above.</p><p>The logP was calculated according to the following equation:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dissociation</head><p>The stability of HIPs was assessed by evaluating the dissociation behavior under physiological conditions. HIPs were dispersed in PBS pH 7.4 and 0.01 M HCl pH 2.0 in concentrations of 1 mg/mL <ref type="bibr" target="#b27">[28]</ref> and incubated for 4 h at 37 °C while shaking on a thermomixer at 300 rpm. Subsequently, mixtures were centrifuged for 15 min at 12,500 rpm, and aliquots of 100 µL were withdrawn from the supernatant and free heparin was quantified via TBO assay, pDNA was spectrophotometrically quantified as described above.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>logP = log Concentration of drug in octanol Concentration of drug in water</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical data analysis</head><p>Statistical data analysis was performed on GraphPad Prism (version 5.1) using the student t-test and the analysis of variance (ANOVA) followed by Bonferroni correction with p ≤ 0.05 as the minimal level of significance. All values are expressed as means ± SD.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results and discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Synthesis of His-surfactants</head><p>Four His-surfactants were successfully prepared via esterification reaction between the starting materials Boc-His(Boc)-OSu and lauryl alcohol (HLE), palmitoyl alcohol (HPE), oleyl alcohol (HOE), and 2-hexyl-1-decanol (HDE) as illustrated in Fig. <ref type="figure" target="#fig_2">1</ref>. Boc-protected histidine was employed in order to avoid polymerization of the aminoacid and unwanted reactions on the imidazolium ring. The FT-IR, 1 H-NMR and MS spectra of the synthesized surfactants are presented in the Supplementary Information (Figs. <ref type="figure" target="#fig_2">S1-S6</ref>). C = O vibrations were observed between 1650 and 1710 cm -1 for all His-surfactants. The OH stretching at 3300 cm -1 , typical of alcohols, is not evidenced in the final products. Between 1100 and 1300 cm -1 the C-O stretching bands are evident, confirming the presence of an ester bond with the carboxylic function of histidine (Figs. <ref type="figure" target="#fig_5">S1-S4</ref>). The imidazole functionality of histidine can be detected around 7.4 and 8.8 ppm. The methine and methylene protons in the histidine head group present peaks at 4.39 and 3.19 ppm, respectively. The methylene groups next to the ester show a chemical shift at 4.11 ppm in the cases of HLE, HPE and HOE, while this peak is a bit downfield to 4.03 ppm in the case of HDE due to the neighboring methine. The hydrophobic fatty acid tail has peaks around 0.85 and 1.23 ppm, belonging to the methyl and methylene protons, respectively.</p><p>In the case of HOE, the peak at 5.33 ppm belong to the protons of the double bond, while at 1.99 ppm to the neighboring methylenes in the fatty acid chain (Fig. <ref type="figure">S5</ref>). The MS spectra (Fig. <ref type="figure">S6</ref>) showed the mass of the final products, thereby further confirming the identity and purity of the obtained compounds.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characterization of His-surfactants</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Determination of CMC and pK a</head><p>The CMC of His-surfactants was determined as a function of concentration, as shown in Fig. <ref type="figure" target="#fig_3">2</ref>. It is well known that the micellar behaviour and, consequently, the CMC value in the case of ionizable surfactants is highly influenced by the number of displayed charges per molecule <ref type="bibr" target="#b28">[29]</ref>. Therefore, the determination was executed at two different conditions: unbuffered solutions, where the surfactants may only bear one charge on the primary amine, and at pH 2.0, where both the primary amine and the imidazolium ring are protonated.</p><p>As reported in Fig. <ref type="figure" target="#fig_3">2</ref>, the two plots show a similar trend for every surfactant, implying that the molecules display the same number of positive charges in both conditions. The CMC was determined as the point where the increase in the surfactant concentration did not further reduce the surface tension. All His-surfactants investigated in this work can reduce the surface tension water/air at small concentrations in the following order: HLE &lt; HPE &lt; HDE &lt; HOE.</p><p>In order to determine the pK a of the imidazolium function of the surfactants, 10 mL of 1.0 mM surfactant solution was titrated with 2.5 mM NaOH (Fig. <ref type="figure" target="#fig_2">S7-S10</ref>). The measured pK a values fall in the range of 4.9-6.0, which differ around one unit from the described pK a values for the histidine imidazolium function in literature (Table <ref type="table" target="#tab_1">1</ref>). A possible explanation for this behaviour can be provided by considering the inductive effect exerted by the lipophilic tails. Another explanation is that the formation of micelles is known to cause pK a shifts <ref type="bibr" target="#b28">[29]</ref>. In the latter case, differences in the polarity of the bulk solvent and the interfacial region cause a change in the pKa of the solubilized species, as described by El Seoud <ref type="bibr" target="#b32">[33]</ref>. In fact, the pK a values, with the only exception of HLE, have been determined by titration of a surfactant solution at a concentration above the CMC.</p><p>Surfactants are amphiphilic molecules and, due to their nature, have a spontaneous tendency to accumulate at interfaces resulting in an inaccurate determination of the partition coefficient between water and octanol. Moreover, surfactants tend to form supramolecular aggregates at a concentration above the CMC, and this can lead to considerable overestimation of the surfactant concentration in the aqueous phase. As Short et al. reported, if the concentration is sufficiently high (i.e., &gt; 10 -2 M) but still below the CMC of the surfactants, the logP can be accurately determined via the classic shake flask method <ref type="bibr" target="#b33">[34]</ref>. In this case, the CMCs determined for the His-surfactants fall in the range of 0.25 to 6 mM (Table <ref type="table" target="#tab_1">1</ref>), consequently, this consideration is not applicable. For the above-mentioned reasons, in this work, only logP values utilizing XLOGP3 software are reported (Table <ref type="table" target="#tab_1">1</ref>). Since surfactants are often used as counterions for hydrophobic ion pairing with hydrophilic drugs in order to increase their lipophilicity for incorporation in lipophilic nanocarrier systems, a comparatively high logP is advantageous. The obtained values are in the range 4.63-7.27, similarly to already reported values in literature for other cationic counterions used in hydrophobic ion pairing <ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Enzymatic biodegradation of his-surfactants</head><p>Trypsin was chosen as the model endogenous enzyme to evaluate the biodegradation of His-surfactants. Overall, the degradation of His-surfactants was completed within 24 h, with the only exception of HDE (Fig. <ref type="figure" target="#fig_4">3</ref>). In the case of HDE, approximately 40% could be degraded within the first 4 h and no degradation was observed after this time point. Since 2-hexyl-1-decanol is most hydrophobic showing an aqueous solubility of 0.001 g/L, as specified by the manufacturer, it will likely co-precipitate with the conjugate during the cleavage process. Consequently, not the entire substrate could be degraded by trypsin. HLE ester bond was rapidly cleaved, showing a half-life of 1 h. The His-surfactants showed the following order of stability towards enzymatic degradation: HLE &lt; HPE &lt; HOE &lt; HDE, supporting the role also of the lipophilicity and bulkiness of the alkyl chain in preventing enzymatic cleavage. Therefore, the outcome of the study encourages the use of these compounds for pharmaceutical applications because of the ability that endogenous enzymes, such as trypsin, have to cleave the ester bond and break down these compounds into naturally occurring, non-toxic building blocks.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cytotoxicity</head><p>In order to further confirm a reduced cytotoxic potential of the newly produced surfactants, resazurin assays on Caco-2 cells were performed. Within this assay, metabolically active cells reduce the nonfluorescent dye resazurin to the highly fluorescent resorufin enabling the assessment of cell viability. The results are shown in Fig. <ref type="figure" target="#fig_5">4</ref>. Below the CMC, every tested molecule showed cell viabilities &gt; 80% and was considered as non-cytotoxic. At the CMC, HLE and HOE proved to be cytotoxic to some extent (cell viabilities of 40.6% and 53.9%, respectively); at a concentration twice as high as the CMC, also HDE showed a cytotoxic effect with cell viability of 62.4%. In general, two main mechanisms can explain surfactants cytotoxicity: osmotic lysis and solubilization mechanism. The first is predominant at concentrations below the CMC, while the second prevails at concentrations above the CMC <ref type="bibr" target="#b40">[41]</ref>. Aside from the concentration, two structure-related factors strongly influence the surfactants-mediated cytotoxicity: the cationic charge density and hydrophobicity. Given the fact that these agents bear a biocompatible group with reduced cationic charge density as polar heads, the alkyl chain hydrophobicity seems to play a key role in determining their cytotoxicity. According to the proposed mechanism, HLE should be in theory less cytotoxic than HPE, HOE, and HDE, which is in contradiction to the results obtained. However, this might be explained by the around 30-fold higher concentration of HLE that was necessary because of the tremendously higher CMC value compared to the other surfactants having been tested.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ability to provide endosomal escape</head><p>In order to confirm the applicability of His-surfactants investigated within this study as efficient drug delivery tools, the capacity of His-surfactants to provide endosomal escape was studied. Since the erythrocyte membrane is a well-established model to surfactant-endosomal membrane interactions <ref type="bibr" target="#b41">[42]</ref>, hemolytic activity of Hissurfactants was investigated over concentrations ranging from 0.001 to 0.1 mM, as a function of pH (Fig. <ref type="figure">5</ref>). All surfactants showed a concentration-dependent increase of hemolytic activity, and this behavior is in agreement with the wide literature reporting that surfactants at high concentrations are generally hemolytic <ref type="bibr" target="#b42">[43,</ref><ref type="bibr" target="#b43">44]</ref>.</p><p>A pH-dependent membrane disruption has to be achieved to allow intracellular trafficking of therapeutic compounds. Endosomal compartments have a pH of 5.5-6.2, depending on the endosomal stage <ref type="bibr" target="#b44">[45,</ref><ref type="bibr" target="#b45">46]</ref>. Therefore, a preferential destabilization or solubilization of the endosomal membrane at pH 5.5-6.8 is desirable to allow surfactant-drug complexes to escape to the cytoplasm. On the other hand, low hemolytic activity is expected at the pH range of 7.4-6.8. HPE and HOE met this requirement, showing pH-dependent increase in hemolytic activity in the desired range (Fig. <ref type="figure">5E</ref>). This observation opens the possibility of studying these His-surfactants for these potential uses.</p><p>HDE also proved to be efficient in providing endosomal escape due to the high hemolysis at pH 5.5-6.2 but also shows pronounced hemolysis at physiological pH. Surprisingly, HLE showed an opposite behavior as expected. In the case of HPE, HOE, and HDE hemolysis increased as pH reaches values closer to pK a1 (Fig. <ref type="figure">5E</ref>). In the case of HLE, the positive charge bearded by the imidazolium ring seems to exert a stabilizing effect on the erythrocyte membrane, similarly to previous observations <ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hydrophobic ion pairing</head><p>The potential of His-surfactants to form hydrophobic ion pairs with macromolecular drugs and nucleic acids was evaluated using heparin and pDNA as model drugs. The efficiency of His-surfactants as hydrophobic ion pairing agents was evaluated using molar ratios ranging from 1:2 to 1:50 (heparin:surfactant) and from 1:6159 to 1:18477 (DNA:surfactant). The heparin-surfactant complex formation increased with increasing the molar ratio from 1:2 to 1:20 (Fig. <ref type="figure">6A</ref>) for each compound. All formed HIPs were obtained as white solids except for heparin-HOE which appeared as a yellowish oily phase. Heparin-HOE complexation yields higher precipitation efficiencies in the range of 1:5 -1:10, likely due to its higher hydrophobicity. Overall, each Hissurfactant yielded 100% precipitation efficiency at the molar ratio of 1:20, resulting in higher efficiency than the corresponding arginine-based surfactants <ref type="bibr" target="#b27">[28]</ref>. Theoretically, the maximum precipitation efficiency can be reached when every negative charge is paired with a positive charge. Therefore, a molar ratio of 1:6159 (pDNA:surfactant) was applied, referring to the stoichiometric ratio of charged moieties. On the other hand, the maximum precipitation efficiency could be obtained only at a molar ratio of 1:18477 (pDNA:surfactant) (Fig. <ref type="figure">6B</ref>). This observation might be explained by additional effects influencing precipitation efficiency such as an increase in ionic strength and/or non-ionic interactions between the drug and the counterion or counterion-counterion, as already reported by other authors <ref type="bibr" target="#b26">[27,</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref>. The complexation with His-surfactants allows complete heparin and pDNA complexation and precipitation without any complex re-solubilization due to micelle formation. The obtained results confirm the hypothesis that these compounds can effectively be employed as counterions for hydrophobic ion pairing with hydrophilic macromolecular drugs like heparin and nucleic acids.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characterization of HIPs</head><p>Heparin and pDNA HIPs were further characterized regarding their increase in lipophilicity via evaluation of the partition coefficient water/octanol. The logP of heparin and pDNA was effectively increased by HIP formation with His-surfactants, leading to the formation of a white precipitate in aqueous media. The lipophilicity of heparin and pDNA was increased by more than 300-fold and 3000-fold, respectively (Fig. <ref type="figure">7A,</ref><ref type="figure">B</ref>), enabling their incorporation into lipid-based formulations. In comparison to previous arginine-based surfactants investigated as counterions for heparin HIP <ref type="bibr" target="#b27">[28]</ref> (i.e., arginine nonyl ester and arginine hexadecanoyl ester), the complexes obtained with His-surfactants investigated within this study showed higher lipophilicity. Moreover, in the case of pDNA, HIP allowed to reverse the hydrophilic character of the nucleic acid to lipophilic. Overall, considering the obtained data, increased complex solubilization in lipophilic vehicles employed in lipid-based formulations is expected.</p><p>The stability of the newly formed HIPs was evaluated by determining the dissociation behavior under physiological conditions at pH 7.4 and 2.0 (Fig. <ref type="figure">8A</ref>). At physiological pH, &gt; 50% heparin HIP dissociated within 4 h. On the contrary, the complexes proved to be highly stable under acidic conditions. The same behavior was observed in the case of pDNA HIP. This behavior can be attributed to the pH-dependent charge of His-surfactants. At pH 2.0 the imidazolium function is protonated, and His-surfactants retain their ability to complex heparin and pDNA, but above the pK a1 (pH 7.4), the imidazole does not bear a positive charge anymore, resulting in an increased dissociation of the HIPs. The observed behavior of the investigated HIPs confirms their suitability for drug delivery purposes, as HIPs, once delivered to the site of action, should dissociate in order to allow the drug to exert its function. According to the obtained data, a dissociation under acidic gastrointestinal conditions is not favored. However, PBS, mimicking physiological conditions, can trigger dissociation, thereby enabling the release of the hydrophilic therapeutic agent. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>Within this study, the amino-acid histidine (His) was successfully coupled with naturally occurring fatty alcohols (lauryl, palmitoyl, oleyl) and 2-hexyl-1-decanol via ester bond formation. The obtained surfactants demonstrated the ability to be cleaved by an endogenous enzyme represented by trypsin within 24 h and low cytotoxicity on Caco-2 cell line, representing an eco-and patient-friendly alternative to the commonly employed cationic surfactants. The investigated His-surfactants displayed favorable characteristics regarding hydrophobic ion pair formation with the hydrophilic macromolecular drug heparin and plasmid DNA. Complexation led to complete drug precipitation in aqueous and the resulting complexes exhibited increased lipophilicity. According to the obtained results, the formed His-complexes are promising candidates for incorporation in lipid-based drug delivery systems for oral delivery of heparin and nucleic acids. SEDDS might be employed for this purpose, due to their favorable properties in terms of protection against the harsh gastrointestinal environment, as well as mucus permeating properties. Considering the encouraging outcome of this study, biodegradable His-surfactants might represent a valuable alternative to the established surfactants not only in the pharmaceutical field but also for food and cosmetic industry.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>Histidine-lauryl ester (HLE) Boc-His(Boc)-OSu (452.46 mg, 1 mmol), lauryl alcohol (223.6 mg, 1.2 mmol) and DMAP (14.7 mg, 0.12 mmol) were dissolved in 3 mL of DCM and kept under continuous stirring for 14 h at 35 °C. Subsequently, removal of Boc groups and purification yielded a white solid (225 mg, yield 40.0%). IR ν max 2918, 2851 (sp 3 -CH), 1687 (ester C = O), 1139 cm -1 (ester C-O). 1 H-NMR (DMSOd 6 , 400 MHz) δ = 8.87, 7.42 (2 H, 2s, histidine -CH=), 4.35 (1H, m, -CH(NH 2 )-), 4.11 (2 H, m, histidine -CH 2 -), 3.19 (2 H, m, -C(O)-CH 2 -), 1.51 (2 H, s, -C(O)-CH 2 -CH 2 -), 1.23 (18 H, s, -CH 2 -) 0.85 ppm (3H, m, -CH 3 ). m/z = 324.1 (M + , 324.1%), 325.2 (10).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc>-CH), 1665 (ester C = O), 1131 cm -1 (ester C-O). 1 H-NMR (DMSOd 6 , 400 MHz) δ = 8.85, 7.41 (2 H, s, -CH=), 4.39 (2 H, m, -CH&lt;-), 4.03 (2 H, m, histidine -CH 2 -), 3.19 (2 H, m, -C(O)-CH 2 -), 1.54 (2 H, s, -C(O)-CH 2 -CH&lt;), 1.23 (24 H, s, -CH 2 -) 0.85 ppm (6 H, m, -CH 3 ). m/z = 380.1 (M + , 100%), 380.8 (35), 379.5 (20).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 1</head><label>1</label><figDesc>Fig. 1 Synthesis of HLE, HPE, HOE, and HDE. Tert-butyloxycarbonyl (BOC), 4-dimethylaminopyridine (DMAP), dichloromethane (DCM), and trifluoroacetic acid (TFA)</figDesc><graphic coords="3,56.68,57.76,481.92,170.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 2</head><label>2</label><figDesc>Fig. 2 Plot of surface tension (mN/m) versus surfactant concentration (mM) for A HLE, B HPE, C HOE, and D HDE. E Illustration of Hissurfactants charges at different pH values. Indicated values are means (n ≥ 3) ± SD</figDesc><graphic coords="6,56.68,446.85,481.92,234.36" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 3</head><label>3</label><figDesc>Fig. 3 Enzymatic degradation of A HLE, B HPE, C HOE, and D HDE with trypsin (1000-2000 BAEE units mg -1 ) in 100 mM HEPES buffer at pH 6.8 Indicated values are means (n ≥ 3) ± SD</figDesc><graphic coords="8,56.68,57.76,481.92,432.24" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Fig. 4</head><label>4</label><figDesc>Fig. 4 Cytotoxicity studies on Caco-2 cells of HLE (red bars), HPE (blue bars), HOE (orange bars), and HDE (turquoise bars) after A 4 h and B 24 h incubation at 37 °C using resazurin assay. C Concentration tested for each surfactant. Data are shown as mean ± SD (n = 3)</figDesc><graphic coords="9,56.68,57.76,481.92,293.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Fig. 5 Fig. 6 A</head><label>56</label><figDesc>Fig. 5 Hemolytic activity of His-surfactants. A Dose-dependent hemolysis of HLE. B Dose-dependent hemolysis of HPE. C Dosedependent hemolysis of HOE. D Dose-dependent hemolysis of HDE.</figDesc><graphic coords="10,56.68,57.76,481.92,497.52" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Fig. 7 A◂Fig. 8 (</head><label>78</label><figDesc>Fig. 7 A LogP values (octanol/water partition coefficients) of free heparin and HIPs with His-surfactants. B LogP values (octanol/water partition coefficients) of free pDNA and HIPs with His-surfactants. Data are shown as mean ± SD (n = 3) ◂</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc>-), 3.20 (2 H, m, -C(O)-CH 2 -), 1.99 (2 H, s, -CH 2 -CH=), 1.52 (2 H, s, -C(O)-CH 2 -CH 2 -), 1.23 (22 H, s, -CH 2 -) 0.85 ppm (3H, m, -CH 3 ). m/z = 405.8 (M + , 100%), 403.5</figDesc><table><row><cell>histidine -CH 2</cell></row><row><cell>H-NMR (DMSO-d 6 , 400 MHz) δ = 8.87, 7.42 (2 H,</cell></row><row><cell>s, histidine -CH=), 4.35 (1H, m, -CH(NH 2 )-), 4.11 (2 H, m, histidine -CH 2 -), 3.19 (2 H, m, -C(O)-CH 2 -), 1.51 (2 H,</cell></row><row><cell>s, -C(O)-CH 2 -CH 2 -), 1.23 (24 H, s, -CH 2 -) 0.85 ppm (3H, m, -CH 3 ). m/z = 340.4 (M + , 100%), 379.6 (75), 381.1 (20).</cell></row><row><cell>Histidine-oleyl ester (HOE) Boc-His(Boc)-OSu (452.46 mg,</cell></row><row><cell>1 mmol), oleyl alcohol (322.2 mg, 1.2 mmol) and DMAP</cell></row><row><cell>(14.7 mg, 0.12 mmol) were dissolved in 3 mL of DCM and</cell></row><row><cell>kept under continuous stirring for 14 h at 35 °C. Subse-</cell></row><row><cell>quently, removal of Boc groups and purification yielded a white solid (300 mg, yield 50.4%). IR ν max 2923, 2853 (sp 3 -CH), 1665 (ester C = O), 1133 cm -1 (ester C-O). 1 H-NMR</cell></row><row><cell>(DMSO-d 6 , 400 MHz) δ = 8.85, 7.41 (2 H, s, -CH=), 5.33</cell></row><row><cell>(2 H, s, -CH=), 4.35 (1H, m, -CH(NH 2 )-), 4.11 (2 H, m,</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc>Physicochemical properties of HLE, HPE, HOE, and HDE.</figDesc><table><row><cell>Compound</cell><cell>Formula</cell><cell>Molecular Weight (g/mol)</cell><cell>cLogP</cell><cell>Apparent pK a (imidazolium)</cell><cell>CMC (mM) unbuffered</cell><cell>CMC (mM)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>pH = 2</cell></row><row><cell>HLE</cell><cell>C 18 H 33 N 3 O 2</cell><cell>323.26 a</cell><cell>4.63 b</cell><cell>6.0</cell><cell>6.00</cell><cell>6.54</cell></row><row><cell>HPE</cell><cell>C 22 H 41 N 3 O 2</cell><cell>379.32 a</cell><cell>6.80 b</cell><cell>4.9</cell><cell>0.54</cell><cell>0.57</cell></row><row><cell>HOE</cell><cell>C 24 H 43 N 3 O 2</cell><cell>405.34 a</cell><cell>7.27 b</cell><cell>5.1</cell><cell>0.25</cell><cell>0.36</cell></row><row><cell>HDE</cell><cell>C 22 H 41 N 3 O 2</cell><cell>379.32 a</cell><cell>6.83 b</cell><cell>5.2</cell><cell>0.75</cell><cell>1.00</cell></row><row><cell cols="2">b Calculated with XLOGP3</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p>a Calculated with ChemDraw</p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgements</head><p>The authors would like to thank <rs type="person">Michael Noisternig</rs> (<rs type="affiliation">Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, 6020 Innsbruck, Austria</rs>) for his kind assistance with the surface tension analysis. The authors would also like to thank <rs type="person">Mariana Blanco Massani</rs> (<rs type="affiliation">Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, 6020 Innsbruck, Austria</rs>) for providing skillful technical assistance.</p></div>
			</div>
			<div type="funding">
<div><p>Funding Open access funding provided by <rs type="funder">University of Innsbruck and Medical University of Innsbruck</rs>. This work was supported by <rs type="funder">EUREGIO</rs> (<rs type="grantNumber">IPN178 -CUP H35F21001410003</rs>).</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_C6EERrT">
					<idno type="grant-number">IPN178 -CUP H35F21001410003</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data availability</head><p>The authors confirm that the data supporting the findings of this study are available within the article and its supplementary information files. The datasets generated during or analyzed during the current study are available from the corresponding author on reasonable request.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Information</head><p>The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s13346-023-01511-8. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Declarations</head><p>Ethics approval and consent to participate Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent for publication Not applicable.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p><p>Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.</p><p>Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Re)defining biopharmaceutical</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Biotechnol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="743" to="751" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers</title>
		<author>
			<persName><forename type="first">S</forename><surname>Haddadzadegan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dorkoosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.addr.2021.114097</idno>
		<ptr target="https://doi.org/10.1016/j.addr.2021.114097" />
	</analytic>
	<monogr>
		<title level="j">Adv Drug Deliv Rev</title>
		<imprint>
			<biblScope unit="volume">182</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Bernkop-Schnürch A. Development and in vitro characterization of selfemulsifying drug delivery system (SEDDS) for oral opioid peptide delivery</title>
		<author>
			<persName><forename type="first">O</forename><surname>Zupančič</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rohrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Thanh</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Grießinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename></persName>
		</author>
		<idno type="DOI">10.1080/03639045.2017.1338722</idno>
		<idno>1080/ 03639 045. 2017. 13387 22</idno>
		<ptr target="https://doi.org/10" />
	</analytic>
	<monogr>
		<title level="j">Drug Dev Ind Pharm</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1694" to="1702" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin</title>
		<author>
			<persName><forename type="first">F</forename><surname>Hintzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hauptstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Laffleur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijpharm.2014.05.047</idno>
		<ptr target="https://doi.org/10.1016/j.ijpharm.2014.05.047" />
	</analytic>
	<monogr>
		<title level="j">Int J Pharm</title>
		<imprint>
			<biblScope unit="volume">472</biblScope>
			<biblScope unit="page" from="20" to="26" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Development and in vitro characterisation of an oral self-emulsifying delivery system for daptomycin</title>
		<author>
			<persName><forename type="first">O</forename><surname>Zupančič</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Partenhauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rohrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejps.2015.10.005</idno>
		<ptr target="https://doi.org/10.1016/j.ejps.2015.10.005" />
	</analytic>
	<monogr>
		<title level="j">Eur J Pharm Sci</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="129" to="136" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">in vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration</title>
		<author>
			<persName><forename type="first">O</forename><surname>Zupančič</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Grieβinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rohrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Pereira De Sousa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Danninger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Partenhauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Sündermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Laffleur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<author>
			<persName><surname>Development</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejpb.2016.09.013</idno>
		<ptr target="https://doi.org/10.1016/j.ejpb.2016.09.013" />
	</analytic>
	<monogr>
		<title level="j">Eur J Pharm Biopharm</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="113" to="121" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Trypsin decorated self-emulsifying drug delivery systems (SEDDS): key to enhanced mucus permeation</title>
		<author>
			<persName><forename type="first">I</forename><surname>Shahzadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dizdarević</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Efiana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Matuszczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcis.2018.07.057</idno>
		<ptr target="https://doi.org/10.1016/j.jcis.2018.07.057" />
	</analytic>
	<monogr>
		<title level="j">J Colloid Interface Sci</title>
		<imprint>
			<biblScope unit="volume">531</biblScope>
			<biblScope unit="page" from="253" to="260" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Development and in vitro characterization of a papain loaded mucolytic self-emulsifying drug delivery system (SEDDS)</title>
		<author>
			<persName><forename type="first">C</forename><surname>Leichner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Menzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Laffleur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijpharm.2017.08.059</idno>
		<ptr target="https://doi.org/10.1016/j.ijpharm.2017.08.059" />
	</analytic>
	<monogr>
		<title level="j">Int J Pharm</title>
		<imprint>
			<biblScope unit="volume">530</biblScope>
			<biblScope unit="page" from="346" to="353" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Hydrophobic ion pairing: altering the Solubility properties of Biomolecules</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Manning</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharm Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="188" to="193" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Development and in vitro evaluation of an oral SEDDS for desmopressin</title>
		<author>
			<persName><forename type="first">O</forename><surname>Zupančič</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Leonaviciute</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Partenhauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Podričnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.3109/10717544.2016.1143056</idno>
		<ptr target="https://doi.org/" />
	</analytic>
	<monogr>
		<title level="j">Drug Deliv</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2074" to="2083" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bonengel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jelkmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abdulkarim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gumbleton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Reinstadler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Oberacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Prüfert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jconrel.2018.01.012</idno>
		<ptr target="https://doi.org/10.1016/j.jconrel.2018.01.012" />
	</analytic>
	<monogr>
		<title level="j">J Controlled Release</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page" from="21" to="29" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Ristroph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">'</forename><surname>Prud</surname></persName>
		</author>
		<author>
			<persName><surname>Rk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nanoscale Adv</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="4207" to="4237" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Self-emulsifying peptide drug delivery systems: how to make them highly mucus permeating</title>
		<author>
			<persName><forename type="first">J</forename><surname>Griesser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hetényi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kadas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Demarne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Jannin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijpharm.2018.01.018</idno>
		<ptr target="https://doi.org/10.1016/j.ijpharm.2018.01.018" />
	</analytic>
	<monogr>
		<title level="j">Int J Pharm</title>
		<imprint>
			<biblScope unit="volume">538</biblScope>
			<biblScope unit="page" from="159" to="166" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Peptide release from SEDDS containing hydrophobic ion pair therapeutic peptides measured by Taylor dispersion analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Chamieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Domènech</forename><surname>Tarrat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Doudou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jannin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Demarne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cottet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.ijpharm.2019.01.039</idno>
		<idno>01. 039</idno>
		<ptr target="https://doi.org/10.1016/j.ijpharm" />
	</analytic>
	<monogr>
		<title level="j">Int J Pharm</title>
		<imprint>
			<biblScope unit="volume">559</biblScope>
			<biblScope unit="page" from="228" to="234" />
			<date type="published" when="2019">2019. 2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ismail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tnq</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Laffleur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Csóka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejpb.2020.04.025</idno>
		<ptr target="https://doi.org/10.1016/j.ejpb.2020.04.025" />
	</analytic>
	<monogr>
		<title level="j">Eur J Pharm Biopharm</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="10" to="17" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The Effect of counterions in hydrophobic ion pairs on oral bioavailability of Exenatide</title>
		<author>
			<persName><forename type="first">Tnq</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ismail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><forename type="middle">-</forename><surname>Vinh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zaichik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Laffleur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<idno type="DOI">10.1021/acsbiomaterials.0c00637</idno>
		<ptr target="https://doi.org/10.1021/acsbiomaterials" />
	</analytic>
	<monogr>
		<title level="j">ACS Biomater Sci Eng</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">37</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Lipophilic salts and lipid-based formulations: enhancing the oral delivery of Octreotide</title>
		<author>
			<persName><forename type="first">P</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Haque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Mcinerney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Scammells</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Jannin</surname></persName>
		</author>
		<author>
			<persName><surname>Christopher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Benameur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Pouton</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11095-021-03063-3/Published</idno>
		<ptr target="https://doi.org/10.1007/s11095-021-03063-3/Published" />
	</analytic>
	<monogr>
		<title level="j">Pharm Res</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1125" to="1137" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Mechanisms of action of ionic liquids on living cells: the state of the art</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kumari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vvs</forename><surname>Pillai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benedetto</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12551-020-00754-w/Published</idno>
		<ptr target="https://doi.org/10.1007/s12551-020-00754-w/Published" />
	</analytic>
	<monogr>
		<title level="j">Biophys Rev</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1187" to="1215" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Correlation of the cytotoxic effects of cationic lipids with their headgroups</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1039/c8tx00005k</idno>
		<ptr target="https://doi.org/10" />
	</analytic>
	<monogr>
		<title level="j">Toxicol Res (Camb)</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">5</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems</title>
		<author>
			<persName><forename type="first">M</forename><surname>Packer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gyawali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Yerabolu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schariter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>White</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-021-26926-0</idno>
		<ptr target="https://doi.org/10.1038/s41467-021-26926-0" />
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Toxicity of cationic lipids and cationic polymers in gene delivery</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lv</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jconrel.2006.04.014</idno>
		<ptr target="https://doi.org/10.1016/j.jconrel.2006.04.014" />
	</analytic>
	<monogr>
		<title level="j">J Control Release</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="100" to="109" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Biological properties of arginine-based glycerolipidic cationic surfactants</title>
		<author>
			<persName><forename type="first">N</forename><surname>Pérez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pérez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Infante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>García</surname></persName>
		</author>
		<idno type="DOI">10.1039/b419204d</idno>
		<ptr target="https://doi.org/10.1039/b419204d" />
	</analytic>
	<monogr>
		<title level="j">Green Chem</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="540" to="546" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Green amino acid-based surfactants</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Morán</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pinazo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pérez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Clapés</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Angelet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>García</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Vinardell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Infante</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Green Chem</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="233" to="240" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">PH-sensitive surfactants from lysine: Assessment of their cytotoxicity and environmental behavior. Langmuir</title>
		<author>
			<persName><forename type="first">A</forename><surname>Colomer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pinazo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>García</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mitjans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Vinardell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Infante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Martínez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pérez</surname></persName>
		</author>
		<idno type="DOI">10.1021/la203974f</idno>
		<ptr target="https://doi.org/10.1021/la" />
		<imprint>
			<date type="published" when="2012">2012</date>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page">974</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">The role of counterions in the membrane-disruptive properties of pH-sensitive lysine-based surfactants</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Nogueira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mitjans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Infante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Vinardell</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.actbio.2011.03.017</idno>
		<ptr target="https://doi.org/10.1016/j.actbio.2011.03.017" />
	</analytic>
	<monogr>
		<title level="j">Acta Biomater</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="2846" to="2856" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Cationic surfactants from lysine: synthesis, micellization and biological evaluation</title>
		<author>
			<persName><forename type="first">L</forename><surname>Pérez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pinazo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Teresa</forename><surname>García</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lozano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Manresa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Angelet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Pilar</forename><surname>Vinardell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mitjans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Rosa</forename><surname>Infante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.ejmech.2008.11.003</idno>
		<ptr target="https://doi.org/10.1016/j.ejmech.2008.11.003" />
	</analytic>
	<monogr>
		<title level="j">Eur J Med Chem</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1884" to="1892" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Biodegradable arginine based steroid-surfactants: cationic green agents for hydrophobic ion-pairing</title>
		<author>
			<persName><forename type="first">Matteo</forename><surname>Jörgensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Knoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Haddadzadegan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fabian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hupfauf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Georg</forename><surname>Jörgensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.ijpharm.2022.122438</idno>
		<ptr target="https://doi.org/10.1016/j.ijpharm.2022.122438" />
	</analytic>
	<monogr>
		<title level="j">Int J Pharm</title>
		<imprint>
			<biblScope unit="volume">630</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Arginine-based cationic surfactants: biodegradable auxiliary agents for the formation of hydrophobic ion pairs with hydrophilic macromolecular Drugs</title>
		<author>
			<persName><forename type="first">I</forename><surname>Shahzadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Asim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dizdarević</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kurpiers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Matuszczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcis.2019.05.057</idno>
		<ptr target="https://doi.org/10.1016/j.jcis.2019.05.057" />
	</analytic>
	<monogr>
		<title level="j">J Colloid Interface Sci</title>
		<imprint>
			<biblScope unit="volume">552</biblScope>
			<biblScope unit="page" from="287" to="294" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Aggregation behavior, antibacterial activity and biocompatibility of catanionic assemblies based on amino acid-derived surfactants</title>
		<author>
			<persName><forename type="first">L</forename><surname>Pérez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pinazo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Morán</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pons</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms21238912</idno>
		<ptr target="https://doi.org/10.3390/ijms" />
	</analytic>
	<monogr>
		<title level="j">Int J Mol Sci</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="12389" to="12401" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Efficient and specific trypsin digestion of microgram to nanogram quantities of proteins in organic-aqueous solvent systems</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Strader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Tabb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Hervey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Hurst</surname></persName>
		</author>
		<idno type="DOI">10.1021/ac051348l</idno>
		<ptr target="https://doi.org/10.1021/ac051348l" />
	</analytic>
	<monogr>
		<title level="j">Anal Chem</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="125" to="134" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">PH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Manganiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Opara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Convertine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Stayton</surname></persName>
		</author>
		<idno type="DOI">10.1021/nn305466z</idno>
		<ptr target="https://doi.org/10.1021/nn" />
	</analytic>
	<monogr>
		<title level="j">ACS Nano</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">466</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Immobilization of heparin/poly-Llysine nanoparticles on dopamine-coated surface to create a heparin density gradient for selective direction of platelet and vascular cells behavior</title>
		<author>
			<persName><forename type="first">T</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Maitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.actbio.2013.12.013</idno>
		<ptr target="https://doi.org/10.1016/j.actbio.2013.12.013" />
	</analytic>
	<monogr>
		<title level="j">Acta Biomater</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1940" to="1954" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Effects of organized surfactant assemblies on acidbase equilibria</title>
		<author>
			<persName><forename type="first">El</forename><surname>Seoud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename></persName>
		</author>
		<idno type="DOI">10.1016/0001-8686(89)80002-8</idno>
		<ptr target="https://doi.org/10.1016/0001-8686" />
	</analytic>
	<monogr>
		<title level="j">Adv Colloid Interface Sci</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="80002" to="80008" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Practical methods for the measurement of logP for surfactants</title>
		<author>
			<persName><forename type="first">J</forename><surname>Short</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hodges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gutsell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Ward</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ecoenv.2010.03.006</idno>
		<ptr target="https://doi.org/10.1016/j.ecoenv.2010.03.006" />
	</analytic>
	<monogr>
		<title level="j">Ecotoxicol Environ Saf</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1484" to="1489" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: Preparation, characterization, and in vivo oral bioavailability and anticancer effect</title>
		<author>
			<persName><forename type="first">R</forename><surname>Pangeni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">U</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Panth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Byun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.2147/IJN.S167958</idno>
		<ptr target="https://doi.org/10.2147/IJN.S1679" />
	</analytic>
	<monogr>
		<title level="j">Int J Nanomedicine</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">58</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Allr</forename><surname>Coelho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gab</forename><surname>Mahecha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Oréfice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lam</forename><surname>Ferreira</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijpharm.2009.07.025</idno>
		<ptr target="https://doi.org/10.1016/j.ijpharm.2009.07.025" />
	</analytic>
	<monogr>
		<title level="j">Int J Pharm</title>
		<imprint>
			<biblScope unit="volume">381</biblScope>
			<biblScope unit="page" from="77" to="83" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Encapsulation of the synthetic retinoids Am80 and LE540 into polymeric micelles and the retinoids&apos; release control</title>
		<author>
			<persName><forename type="first">T</forename><surname>Satoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Higuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kawakami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hashida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kagechika</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shudo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yokoyama</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jconrel.2009.02.024</idno>
		<ptr target="https://doi.org/10.1016/j.jconrel.2009.02.024" />
	</analytic>
	<monogr>
		<title level="j">J Controlled Release</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="187" to="195" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Formation of ion pairing as an alternative to improve encapsulation and anticancer activity of all-trans retinoic acid loaded in solid lipid nanoparticles</title>
		<author>
			<persName><forename type="first">G</forename><surname>Carneiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Pacheco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>De Souza-Fagundes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ncr</forename><surname>Corrêa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>De Goes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>De Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lam</forename><surname>Ferreira</surname></persName>
		</author>
		<idno type="DOI">10.2147/IJN.S38953</idno>
		<ptr target="https://doi.org/10.2147/IJN.S38953" />
	</analytic>
	<monogr>
		<title level="j">Int J Nanomedicine</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="6011" to="6020" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Improved in vitro antileukemic activity of all-trans retinoic acid loaded in cholesteryl butyrate solid lipid nanoparticles</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Lima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Carneiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Gomes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Souza-Fagundes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lam</forename></persName>
		</author>
		<idno type="DOI">10.1166/jnn.2016.11677</idno>
		<ptr target="https://doi.org/10.1166/jnn.2016.11677" />
	</analytic>
	<monogr>
		<title level="j">J Nanosci Nanotechnol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1291" to="1300" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Development of a new solid lipid nanoparticle formulation containing retinoic acid for topical treatment of acne</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Oréfice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jmc</forename><surname>Vilela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Andrade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lam</forename><surname>Ferreira</surname></persName>
		</author>
		<idno type="DOI">10.1080/02652040701288519</idno>
		<ptr target="https://doi.org/" />
	</analytic>
	<monogr>
		<title level="j">J Microencapsul</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="395" to="407" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Structure-activity relationship of cationic surfactants as antimicrobial agents</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Colloid Interface Sci</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="28" to="43" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Ex vivo Red Blood Cell Hemolysis Assay for the evaluation of pH-responsive Endosomolytic agents for Cytosolic Delivery of Biomacromolecular Drugs</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Beavers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Giorgio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Duvall</surname></persName>
		</author>
		<idno type="DOI">10.3791/50166</idno>
		<ptr target="https://doi.org/10.3791/50166" />
	</analytic>
	<monogr>
		<title level="j">J Visualized Experiments</title>
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Permeability alterations and antihaemolysis induced by amphiphiles in human erythrocytes</title>
		<author>
			<persName><forename type="first">B</forename><surname>Isomaa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hägerstrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Paatero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Engblom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochim Biophys Acta</title>
		<imprint>
			<biblScope unit="volume">860</biblScope>
			<biblScope unit="page" from="510" to="524" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Monocatenary histidine-based surfactants: role of the alkyl chain length in antimicrobial activity and their selectivity over red blood cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bustelo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pinazo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Manresa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mitjans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Vinardell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pérez</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.colsurfa.2017.04.017</idno>
		<ptr target="https://doi.org/10.1016/j.colsurfa.2017.04.017" />
	</analytic>
	<monogr>
		<title level="j">Colloids Surf a Physicochem Eng Asp</title>
		<imprint>
			<biblScope unit="volume">532</biblScope>
			<biblScope unit="page" from="501" to="509" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">pH in the endosome. Measurements during Pinocytosis and Receptor-mediated Endocytosis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Geisow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Evans</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Endosome pH measured in single cells by dual fluorescence Flow Cytometry: Rapid Acidification of insulin to pH 6</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Powers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Cantor</surname></persName>
		</author>
		<idno type="DOI">10.1083/jcb.98.5.1757</idno>
		<ptr target="https://doi.org/10.1083/jcb.98.5.1757" />
	</analytic>
	<monogr>
		<title level="j">J Cell Biol</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="1757" to="1762" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Hemolysis and antihemolysis induced by amino acid-based surfactants</title>
		<author>
			<persName><forename type="first">L</forename><surname>Sánchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Martínez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rosa</forename><surname>Infante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mitjans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Pilar</forename><surname>Vinardell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1016/J.TOXLET.2007.01.003</idno>
		<idno>1016/J. TOXLET. 2007. 01. 003</idno>
		<ptr target="https://doi.org/10" />
	</analytic>
	<monogr>
		<title level="j">Toxicol Lett</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="177" to="184" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Interactions of surface-active alkyltrimethylammonium salts with the erythrocyte membrane</title>
		<author>
			<persName><forename type="first">B</forename><surname>Isomaa</surname></persName>
		</author>
		<idno type="DOI">10.1016/0006-2952(79)90289-2</idno>
		<ptr target="https://doi.org/10.1016/0006-2952" />
	</analytic>
	<monogr>
		<title level="j">Biochem Pharmacol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="90289" to="90291" />
			<date type="published" when="1979">1979</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Volume expansion of erythrocytes is not the only mechanism responsible for the protection by arginine-based surfactants against hypotonic hemolysis</title>
		<author>
			<persName><forename type="first">Fait</forename><surname>Hermet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vazquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Daza</forename><surname>Millone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Vela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Morcelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Bakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
		<idno type="DOI">10.1016/J.COLSURFB.2018.07.005</idno>
		<ptr target="https://doi.org/10.1016/J.COLSURFB.2018.07.005" />
	</analytic>
	<monogr>
		<title level="j">Colloids Surf B Biointerfaces</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="page" from="134" to="141" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Counterion optimization for hydrophobic ion pairing (HIP): unraveling the key factors</title>
		<author>
			<persName><forename type="first">V</forename><surname>Claus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sandmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Spleis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lindner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kalb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijpharm.2023.123507</idno>
		<ptr target="https://doi.org/10.1016/j.ijpharm.2023.123507" />
	</analytic>
	<monogr>
		<title level="j">Int J Pharm</title>
		<imprint>
			<biblScope unit="volume">647</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">PEG-PGA enveloped octaarginine-peptide nanocomplexes: an oral peptide delivery strategy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Samaridou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Jaumain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Coëne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ullio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Shrestha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Durán-Lobato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tovar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Santander-Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Lozano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Arroyo-Jimenez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ramos-Membrive</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Peñuelas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mabondzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Préat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Teixidó</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Giralt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Alonso</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jconrel.2018.03.004</idno>
		<ptr target="https://doi.org/10.1016/j.jconrel.2018.03.004" />
	</analytic>
	<monogr>
		<title level="j">J Controlled Release</title>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="page" from="125" to="139" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Synthesis and evaluation of sulfosuccinate-based surfactants as counterions for hydrophobic ion pairing</title>
		<author>
			<persName><forename type="first">R</forename><surname>Wibel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Knoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><forename type="middle">-</forename><surname>Vinh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bernkop-Schnürch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.actbio.2022.03.013</idno>
		<ptr target="https://doi.org/10.1016/j.actbio.2022.03.013" />
	</analytic>
	<monogr>
		<title level="j">Acta Biomater</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="54" to="66" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
